Idioma:

Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial

Zhu, Zilong ; Fu, Ying ; Tian, Decai ; Sun, Na ; Han, Wei ; Chang, Guoqiang ; Dong, Yinhua ; Xu, Xiaolin ; Liu, Qiang ; Huang, DeRen ; Shi, Fu-Dong

Circulation (New York, N.Y.), 2015-09, Vol.132 (12), p.1104-1112 [Periódico revisado por pares]

United States: by the American College of Cardiology Foundation and the American Heart Association, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial
Autor: Zhu, Zilong ; Fu, Ying ; Tian, Decai ; Sun, Na ; Han, Wei ; Chang, Guoqiang ; Dong, Yinhua ; Xu, Xiaolin ; Liu, Qiang ; Huang, DeRen ; Shi, Fu-Dong
Assuntos: B-Lymphocytes - drug effects ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Edema, Cardiac - prevention & control ; Female ; Fibrinolytic Agents - pharmacology ; Fibrinolytic Agents - therapeutic use ; Fingolimod Hydrochloride - pharmacology ; Fingolimod Hydrochloride - therapeutic use ; Humans ; Immunologic Factors - pharmacology ; Immunologic Factors - therapeutic use ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Myocardial Reperfusion Injury - prevention & control ; Pilot Projects ; Recovery of Function - drug effects ; Stroke - drug therapy ; Stroke - pathology ; T-Lymphocytes - drug effects ; Tissue Plasminogen Activator - pharmacology ; Tissue Plasminogen Activator - therapeutic use ; Treatment Outcome
É parte de: Circulation (New York, N.Y.), 2015-09, Vol.132 (12), p.1104-1112
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
Descrição: BACKGROUND—Inflammatory and immune responses triggered by brain ischemia worsen clinical outcomes of stroke and contribute to hemorrhagic transformation, massive edema, and reperfusion injury associated with intravenous alteplase. We assessed whether a combination of the immune-modulator fingolimod and alteplase is safe and effective in attenuating reperfusion injury in patients with acute ischemic stroke treated within the first 4.5 hours of symptom onset. METHODS AND RESULTS—In this multicenter trial, we randomly assigned 25 eligible patients with hemispheric ischemic stroke stemming from anterior or middle cerebral arterial occlusion to receive alteplase alone and 22 patients to receive alteplase plus oral fingolimod 0.5 mg daily for 3 consecutive days within 4.5 hours of the onset of ischemic stroke. Compared with patients who received alteplase alone, patients who received the combination of fingolimod with alteplase exhibited lower circulating lymphocytes, smaller lesion volumes (10.1 versus 34.3 mL; P=0.04), less hemorrhage (1.2 versus 4.4 mL; P=0.01), and attenuated neurological deficits in National Institute of Health Stroke Scales (4 versus 2; P=0.02) at day 1. Furthermore, restrained lesion growth from day 1 to 7 (−2.3 versus 12.1 mL; P<0.01) with a better recovery at day 90 (modified Rankin Scale score 0–1, 73% versus 32%; P<0.01) was evident in patients given fingolimod and alteplase. No serious adverse events were recorded in all patients. CONCLUSIONS—In this pilot study, combination therapy of fingolimod and alteplase was well tolerated, attenuated reperfusion injury, and improved clinical outcomes in patients with acute ischemic stroke. These findings need to be tested in further clinical trials. CLINICAL TRIAL REGISTRATION—URLhttp://www.clinicaltrials.gov. Unique identifierNCT02002390.
Editor: United States: by the American College of Cardiology Foundation and the American Heart Association, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial

Zhu, Zilong ; Fu, Ying ; Tian, Decai ; Sun, Na ; Han, Wei ; Chang, Guoqiang ; Dong, Yinhua ; Xu, Xiaolin ; Liu, Qiang ; Huang, DeRen ; Shi, Fu-Dong

United States: by the American College of Cardiology Foundation and the American Heart Association, Inc

Buscando em bases de dados remotas. Favor aguardar.